se of Expiratory Muscle Strength Training (EMST) in the treatment of dysarthria associated with Parkinsons Disease.

Illawarra Shoalhaven Local Health District0 sites2 target enrollmentFebruary 16, 2021

Overview

No summary available.

Registry

who.int

Start Date

February 16, 2021

End Date

TBD

Last Updated

5 years ago

Study Type

Interventional

Sex

All

Sponsor

•Idiopathic Parkinsons disease, as diagnosed by a neurologist.
•\-Presence of hypokinetic dysarthria as per perceptual speech pathology assessment, with characteristics including decreased volume and decline in speech articulation. To avoid ceiling effect, the study is only to include those with average conversational speaking volume lower than 70dB SLP (measured using a sound pressure meter, at 50cm distance), and with speech intelligibility (as measured on the ‘Frenchay Dysarthria’ assessment) under 90%.
•\-Adults of any age, gender, or time post onset/diagnosis of Parkinsons Disease.
•\-Considered by the primary researcher as cognitively able to follow the EMST treatment protocol (this may be with assistance from a carer).
•\-Willingness to participate in the stated treatment program, to keep records of completed treatment, and to disclose any changes to medical status or interventions within the course of the treatment period.

•Participants will be excluded if they:
•\-Are currently undergoing any other form of voice or speech treatment.
•\-Have previously undergone intervention targeting hypokinetic dysarthria.
•\-Have any medical interventions that may impact their voice, speech, or Parkinsons Disease symptoms (e.g. deep brain stimulation adjustment, phonosurgery, changes to their medication cycle), planned over the period of EMST treatment
•\-Have any contraindications as per the ‘EMST\-150’ device manual, i.e. suspected pregnancy, untreated hypertension, recent stroke or high risk of stroke, cardiac abnormalities, asthma or COPD, history of collapsed lung, head/neck surgery, untreated GORD.